Serono Adds Newron Parkinson's Disease Agent Safinamide With Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies are investigating safinamide as an add-on therapy to dopamine agonists in early Parkinson's disease patients.
You may also be interested in...
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.